三种不同制造商生产的灭活脊髓灰质炎疫苗在二价口服脊髓灰质炎疫苗后接种1或2剂额外剂量时具有等效的安全性和免疫原性:拉丁美洲随机对照试验结果
这项多中心IV期随机对照试验纳入900名拉丁美洲婴儿,比较三种制造商生产的灭活脊髓灰质炎疫苗(IPV)在接种二价口服脊髓灰质炎疫苗(bOPV)后接种1剂或2剂的安全性和免疫原性。结果显示,接种1剂后2型血清转化率在73.3%至80.4%之间,接种2剂后各制造商均不低于99%;含1剂或2剂IPV后粪便排毒指数终点无显著差异,所有疫苗均安全,未发生疫苗相关严重不良事件或重要医学事件。
要点
- 接种1剂IPV后4周,SP-1、GSK-1和BBio-1组2型血清转化率分别为80.4%、80.4%和73.3%。
- 接种2剂IPV后4周,三种制造商疫苗的2型血清转化率均不低于99%。
- 接种1剂或2剂IPV后粪便排毒指数终点无显著差异,所有疫苗均安全。
核心结论
- 当前世界卫生组织预认证的IPV疫苗安全,接种1剂或2剂后诱导相似的体液免疫和肠道免疫。
研究设计与样本
- 多中心IV期随机对照试验,900名拉丁美洲婴儿随机分配至六个研究组,在6、10和14周接种三剂bOPV,并在14周接种1剂IPV(SP-1、GSK-1和BBio-1组)或在14和36周接种2剂IPV(SP-2、GSK-2和BBio-2组),IPV来自三种不同制造商。
- 儿童在18周(接种1剂IPV者)或40周(接种2剂IPV者)接受mOPV2挑战,每周采集粪便持续4周以评估病毒排毒。
- 在疫苗接种前后多个时间点测量血清中和抗体,并在最后一剂研究疫苗后6个月内监测严重不良事件和重要医学事件。
主要发现
- 第18周(接种1剂IPV后4周),SP-1、GSK-1和BBio-1组总体2型血清转化率分别为80.4%、80.4%和73.3%。
- 在IPV接种前血清阴性的婴儿中,第18周2型血清转化率分别为92.6%、96.8%和88.0%。
- 第40周(接种第二剂IPV后4周),三种制造商疫苗的2型血清转化率均不低于99%。
- 接种1剂或2剂IPV后粪便排毒指数终点无显著差异:SP组为2.3(95%CI:2.1-2.6),GSK组为2.2(95%CI:1.7-2.5),BBio组为1.8(95%CI:1.5-2.3)。
- 所有疫苗均安全,未发生疫苗相关严重不良事件或重要医学事件。
关键数值与推荐
- 第18周(接种1剂IPV后4周)总体2型血清转化率:SP-1组80.4%,GSK-1组80.4%,BBio-1组73.3%。
- 第18周(接种1剂IPV后4周)IPV接种前血清阴性者2型血清转化率:SP-1组92.6%,GSK-1组96.8%,BBio-1组88.0%。
- 第40周(接种第二剂IPV后4周)2型血清转化率:三种制造商疫苗均不低于99%。
- 粪便排毒指数终点:SP组2.3(95%CI:2.1-2.6),GSK组2.2(95%CI:1.7-2.5),BBio组1.8(95%CI:1.5-2.3),接种1剂或2剂IPV后无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufacturers. METHODS: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study groups received three doses of bOPV at 6, 10 and 14weeks and either one IPV dose at 14weeks (groups SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36weeks (groups SP-2, GSK-2 and BBio-2) from three different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40weeks (two IPV doses) and stools were collected weekly for 4weeks to assess viral shedding. Serum neutralizing antibodies were measured at various time points pre and post vaccination. Serious adverse events and important medical events (SAE and IME) were monitored for 6months after last study vaccine. RESULTS: At week 18, 4weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4% and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were seronegative before IPV administration. At 40weeks, 4weeks after a second IPV dose, type 2 seroconversion rates were ≥99% for any of the three manufacturers. There were no significant differences in fecal shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1-2.6]); GSK: 2.2 [1.7-2.5]; BBio 1.8 [1.5-2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME. CONCLUSION: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal immunity after one or two doses. The parent study was registered with ClinicalTrials.gov, number NCT01831050.
引用
- Lopez-Medina E, Melgar M, Gaensbauer JT, et al. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America. Vaccine. 2017. PMID: 28455172. doi:10.1016/j.vaccine.2017.04.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。